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ABSTRACT OF DISSERTAION
LYCOPENE AND ITS POTENTIAL NUTRITIONAL ROLE FOR PATIENTS WITH HEART FAILURE

Lycopene is a antioxidant found in natural and processed foods. The connection
between antioxidants and heart disease has been explored in several observational studies1-4,
yet very few investigators have examined the impact of dietary antioxidants in patient with
advanced heart disease such as heart failure (HF). A novel strategy for preventing or delaying
the complications of HF related to inflammation and oxidative stress may be to increase dietary
lycopene.
The purpose of this dissertation was to test the impact of dietary intervention consisting
of lycopene (V8® juice) on biomarkers of inflammation and oxidative stress in patients with HF;
Prior to testing the dietary intervention, preliminary work was conducted: 1) a review of the
literature on dietary lycopene interventions in patients with HF and 2) a longitudinal study to
examine whether lycopene and sodium intake interact to produce an effect on event-free
survival in patients with HF.
Forty patients with HF were randomly assigned to one of two treatment groups
(intervention and usual care). The intervention group received 24 mg of lycopene by drinking
11.5 ounces of V8®100% vegetable juice daily for 30 days. The usual care group continued their
usual diet. Serum levels of uric acid and C-reactive protein were obtained to determine the
impact of the lycopene dietary intervention. Patients in the intervention group had higher
levels of plasma lycopene after one month drinking V8® juice. We also found a significant
decrease in plasma CRP levels among women in the intervention group, while there was no
change in CRP levels among men in the intervention group.

This dissertation has provided insight about lycopene as a potential nutritional
intervention for patients with HF, aimed at reducing inflammation and oxidative stress. This
dietary intervention is practical, easy to replicate, cost effective and is safe for patients with HF.
Additional research is needed to determine the effects of long-term outcomes of dietary
antioxidants in patients with HF.
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CHAPTER ONE
Introduction
Heart failure (HF) is a growing concern for healthcare providers due to upward spiraling
rates of rehospitalizations.5-7 HF places a tremendous economic burden on our healthcare
system with the cost of hospitalizations exceeding 39.2 billons for 2010.8 HF has affected nearly
5.8 million patients in the US, with the American Heart Association (AHA) estimating 670,000
new cases will develop each year.9 Heart failure is primarily a condition of the elderly, as the
incidence of HF approaches 10 cases per 1000 in those over the age of 65.9 10 This condition is
responsible for 900,000 hospitalizations annually, more than for any other medical cause
among the elderly.8
Nutrition could play an important role in the prevention and treatment of HF.11 HF is a
multisystem disorder in which systemic inflammation is a predominant process in the
pathophysiology of HF. Inflammation is a potential target for nutrition therapy.12 However,
current evidence-based guidelines provide very little in the way of recommendations for the
nutritional management of patients with HF.13, 14 The reason for the lack of guideline
recommendations related to nutrition is the limited amount of research in this area.
Certain foods have components that potentially could attenuate inflammatory
processes by providing exogenous antioxidant sources to supplement the endogenous
antioxidant defense system. Oxidative stress occurs when the endogenous antioxidant defense
system is overwhelmed by reactive oxygen species (ROS).15, 16 Reactive oxygen species are
formed intracellularly during mitochondrial electron transport and cause damage to the
myocardium.17-19 The response to myocardial damage is activation of the inflammatory
1

process, which begins with endothelial secretion of chemotatic molecules and can lead to
cardiac dysfunction, cardiac apoptosis and/or necrosis. 18, 19 Thus of particular nutritional
interest is the antioxidant effect of certain bioactive food compounds that potentially reduce
the inflammation process in HF.
There is abundant evidence that dietary patterns characterized by high intake of fruits
and vegetables are associated with a lower risk of obesity, hypertension, diabetes, cancers,
stroke and coronary heart disease, all of which have some degree of systemic inflammation
implicated in their pathophysiology.20-25 The mechanism by which fruits and vegetables reduce
cardiovascular disease risk has not been defined clearly. A plausible explanation may be the
antioxidants present in all fruits and vegetables.26 The bioactivity of antioxidants may account
for the cardioprotective benefit seen when fruits and vegetables are consumed in large
amounts.
Antioxidants are biochemical nutrients found in foods that can prevent or slow the
oxidative damage to the human body, enhance immune defense and lower the risk of
inflammation.27-30 Antioxidants are found abundantly in fruits and vegetables, as well as in
other foods including nuts, grains, and some meats, poultry, and fish. Antioxidants exist in
exogenous and endogenous forms.
Exogenous antioxidants must be obtained through the diet. The most common
exogenous antioxidants are micronutrients like vitamin A, C and E, and phytochemicals such as
flavonoids and carotenoids27 ( see Table 1-1 for a glossary of terms). Endogenous antioxidants
occur naturally in the body. The endogenous antioxidant defense system includes superoxide
dismutase (SOD), glutathione peroxidase (GPx), and catalase(CAT)31 Both forms of antioxidants
2

protect cells from the oxidative stress caused by unstable molecules known as free radicals.
Reactive oxygen species are a type of free radical.28, 30, 32
Free radicals are the natural by-products of normal cell processes. Free radicals are
molecules with incomplete electron shells that make them more chemically reactive than those
with complete electron shells.31 Antioxidants neutralize free radicals by donating one of their
own electrons, ending the electron-"stealing" reaction.30 Despite donating an electron,
antioxidants remain stable and don’t become free radicals themselves. By reducing the
negative consequences of oxidative stress, antioxidants prevent cell and tissue damage that can
lead to disease.17, 30 Under homeostatic conditions, there is balance between oxidative activities
and intracellular levels of antioxidants and this balance is vital for the survival of organisms and
health. 30, 31, 33 The disruption of this balance is thought to be the genesis of a multitude of
diseases. 31, 33
Lycopene is a naturally occurring antioxidant and a micronutrient with important health
benefits. Lycopene exhibits antioxidant action by (1) exerting its strong affinity for singlet
oxygen quenching, (2) protecting cells from lipid peroxidation and (3) enhancing cellular gap
junction communication.34-37 Lycopene may actually stimulate the endogenous enzymatic
antioxidant system.34, 38
Tomatoes and tomato products are a major source of lycopene in the diet.
Approximately 80% of the lycopene consumed in the U. S. comes from processed tomato
products.39 Tomatoes and tomato products are considered healthy as they are cholesterol free,
low in calories and fat, good sources of vitamins A, C & E, as well as potassium and lycopene. A
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diet rich in lycopene-rich food products may have potential health benefits for individuals with
a high oxidative stress load.
The past decade has seen a number of improvements in treatment options for patients
with HF, specifically in pharmacologic regimens. Researchers have gained a better
understanding of the pathophysiology of the condition, but more is needed. Researchers and
clinicians are now looking for less demanding treatment options for the patient with HF. As it
stands, patients with HF must become expert self care clinicians to manage their condition on a
daily basis. Treatment strategies that are easily adapted, low cost, without side effects, and can
be part of a daily routine without intensive external monitoring are needed. Therefore this
dissertation is centered on the research question “Can lycopene, as a potent antioxidant, found
naturally and abundantly in fruits and vegetables, be used as a dietary intervention in patients
with HF to reduce inflammation and improve outcomes?”
In chapter two of this dissertation, the results of a critical review of the literature
related to antioxidant use in HF are presented. This review began as a broad investigation into
lycopene as an antioxidant. The review then narrowed to focus on research studies using
lycopene as a dietary intervention in HF. Lastly, the review focused specifically on studies in
which patients with HF were enrolled as the sample population to test dietary interventions
with lycopene.
In chapter three of this dissertation, the results of a study designed to determine
whether higher intake of lycopene would be associated with better event free survival in
patients with HF, independent of sodium content are presented. This was a longitudinal,
prospective study of 212 patients with HF. Food diaries were kept by patients for four days. Diet
4

nutrient analysis was performed using Nutrition Data System Software™. Patients were
grouped by the median split of lycopene level of 2471 mcg/day and stratified by daily sodium
intake levels above and below 3 grams. Patients were followed for up to 3 years to collect data
on HF hospitalization and cardiac mortality. Cox proportional hazard regression was used to
compare differences in cardiac event-free survival between higher and lower lycopene intake
groups within each stratum of sodium intake level. Lycopene intake above 2471 mcg/day was
associated with longer cardiac event-free survival compared with lower lycopene intake after
controlling for age, gender, HF etiology, body mass index, NYHA functional class, LVEF, and total
comorbidity score (p = .003). The worst cardiac event-free survival was observed in the low
lycopene intake group regardless of sodium intake level.
In chapter four, results are presented from a randomized, controlled pilot study. This
was a study conducted to determine the feasibility of a lycopene intervention in patients with
HF, assessing for the impact of lycopene intake on biomarkers of inflammation and oxidative
stress. Forty patients with HF (age 66 ± 10, 43% female) were randomized to either a usual care
control group or a 30 day dietary intervention of daily lycopene intake. Patients randomized to
the lycopene group consumed an 11.5 ounce can of V8® low-sodium vegetable juice once a day
for 30 days. This 100% vegetable juice provided 24mg of lycopene. Serum samples of c-reactive
protein (CRP), uric acid and b-type natriuretic peptide (BNP) were obtained pre and post
intervention. Dietary intake was established with 4- randomly placed phone calls to collect 24hour dietary recalls per patient over the 30 days. We used repeated measures ANOVA to test
the impact of the intervention and controlled for disease severity using BNP as a surrogate
measure.
5

Chapter five includes a summary and concluding remarks based on all the chapters.
Recommendations for practice and future research are outlined.
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CHAPTER TWO
Lycopene: A Critical Review of the Literature
Introduction
The purpose of this paper is to critically analyze the literature on the impact of dietary
lycopene interventions on inflammation and oxidative stress in patients with HF. Research in
the past two decades has found a strong link of the inflammatory response and oxidative stress
with disease progression in HF12, 40-42, yet there is little research about non-drug interventions
to address this problem.
Inflammation in HF
HF has an inflammatory component that is manifested in the following features: 1)
reduced myocardial contractility; 2) left-ventricular dysfunction; 3) reduced cardiac index; and
4) endothelial dysfunction. There are currently three recognized pathways for inflammatory
activation in HF: 1) direct antigenic stimulation, as is the case of a virus or bacteria infecting the
myocardium; 2) activation secondary to cardiac injury such that the myocardium renders
autoimmune type antigens capable of generating an inflammatory response against the heart;
and 3) activation as a result of cytokine release by the cardiac cells, in response to
hemodynamic stress on the vasculature or the cellular level of heart tissue42.
Specific serum biomarkers of inflammatory status in HF have been identified and include
C-reactive protein (CRP). This biomarker has been studied extensively and has a strong
association with HF disease severity40, 43-46. A basic understanding of the underlying
mechanisms of inflammation, oxidative stress and the antioxidant defense system against a
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permanent threat to myocardial cells is important to understanding why lycopene might be a
potential intervention to reduce inflammation in HF.
Oxidative stress in HF
Oxidation is a normal consequence of cellular metabolism. Oxidative stress is an
abnormal imbalance between the antioxidant system and the byproducts of oxidation. Free
radicals are the result of oxidation, are potentially harmful, but are usually checked by the
antioxidant system. Free radicals are connected with the development of diseases such as
cancer, diabetes, infections, cardiovascular disease and also are thought to play a role in the
aging process 40. The regulation of oxidation is vital for maintenance of cellular homeostasis,
however conditions of excess free radical production (oxidative stress) result in cell damage,
frequently leading to cell and tissue dysfunction and ultimately to conditions such as HF47-49. In
a study by White et al., patients with worsening HF and with a mean ejection fraction (EF) of
23% had evidence of significantly higher levels of biomarkers of oxidative stress and
inflammation when compared to age-matched controls50.
To better understand oxidative stress, a review of the cellular components involved is
important. Mitochondria are considered to be the main cellular source of reactive oxygen
species (ROS; i.e., molecules that result from oxidation) during homeostasis49. Free radicals are
inherently unstable by virtue of their single unpaired electron, thus tending to be highly
reactive and transient. When free radicals come into contact with oxygen, a single electron is
paired and the result is superoxide radical anion47, 49. Superoxide radical anion is considered to
be the starter radical from which all other oxygen radicals are derived. Superoxide anion can act
as both an oxidant and a reductant, depending on the environmental pH and the substrate with
8

which it reacts51. Superoxide radicals are rapidly converted to hydrogen peroxide, and further
catalyzed by enzymes to a hydroxyl radical, which is the most potent oxidant in aerobic
metabolism51. Minimal cellular damage is achieved when the response includes endogenous
and exogenous interacting systems of antioxidant compounds, antioxidants enzymes and repair
enzymes.
Oxidative stress results from increased exposure to oxidants or from decreased
protection against oxidants, both of which may occur simultaneously, thus creating an
imbalance51. The first level of response to oxidative stress is the antioxidant defense and repair
system that minimizes the damage that naturally occurs in the presence of ROS52. Antioxidant
compounds are sacrificed to oxidants in order to directly protect more important cellular
components. Antioxidants have a variety of chemical structures and are either water-soluble or
fat-soluble. Antioxidants are either synthesized in the body (endogenous) or consumed in the
diet (exogenous). Examples of endogenous antioxidants include uric acid, coenzyme Q, lipoic
acid, and some steroid hormones such as estrogens. Dietary antioxidants include vitamins C, E,
carotenoids, and phenolic compounds.
Lycopene
This paper focuses on lycopene as a dietary antioxidant. Lycopene is the most
predominant carotenoid in human plasma. Lycopene is a carotenoid found naturally in plant
sources and has a chemical structure with 11 linearly arranged conjugated double bonds and 2
non-conjugated double bonds53. Because of the high number of conjugated double bonds,
lycopene is considered one of the most potent antioxidants due to its singlet oxygen-quenching
ability 19, 37.
9

More than 600 carotenoids have been discovered and share a common structural
feature, such as a polyisoprenoid structure and conjugated double bonds 53. The chemical
structure of carotenoids is a key determinant of the physical property, chemical reactivity and
biologic function observed36. Carotenoids are strongly influenced by other molecules in the
environment, particularly proteins and lipids. The unique structure and combination of
carotenoids may influence the bioavailability, absorption, circulation and distribution of
lycopene in tissues37 36, 53. Carotenoids are natural pigments synthesized by plants and
microorganisms37. The majority of carotenoids, including lycopene, are without vitamin A
activity. The interest in lycopene has grown recently due to studies that have suggested a role
in human health and disease34, 54.
More than 80% of lycopene consumed in the United States is from tomatoes and
tomato products 54. The primary sources for lycopene in the diet are spaghetti/pasta sauce,
ketchup, salsa, tomato soup, canned tomatoes, raw tomatoes, tomato sauce, tomato paste,
vegetable juice cocktail, and watermelon39. Other fruits such as apricots, guava, papaya and
pink grapefruit also contribute lycopene to the diet. Lycopene concentration varies as a result
of the color and type of tomato. Some deep red varieties contain 50mg per 100 grams of raw
material (about the size of one medium tomato), while yellow varieties contain 5mg/100 grams
(100 grams = 3.5 ounces)39, 54. Lycopene has varied bioavailability and has tissue specific
distribution related to its lipophilic nature; both of these characteristics are important in the
role of an antioxidant 39.
Bioavailability of Lycopene
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Many factors can influence the bioavailability of lycopene, such as the food matrix
containing the lycopene, the absorption rate of the stomach and the co-ingestion of fat as a
delivery medium 37. Thermal processing such as cooking with heat causes a disruption of the
chemical structure of lycopene and enhances bioavailability55, 56. The improved bioavailability of
lycopene from processed foods has also been attributed to its release from the ruptured plant
cells during mechanical processing (grinding, pulverizing) and due to heat induced trans- to cisisomerization57.
The absorption rate in the stomach and duodenum also affects the bioavailability of
lycopene. The action of bile salts and pancreatic lipases assist in the digestion process. Lipids
play an important role in lycopene dissolution and absorption. Lipid droplets containing the
lycopene enter the duodenum and transfer into the mucosal cells via passive diffusion 19, 39, 58.
Chylomicrons carry lycopene from the intestinal mucosa to the blood stream via the lymphatics
39, 58

. Lycopene is transported in the plasma by lipoproteins, and is concentrated in the

hydrophobic core of the lipoprotein particle 39. Experimental studies have been conducted that
suggest it is important to consider bioavailability and food product choice in designing
interventions with lycopene.55, 56, 59-61
Lycopene Interventions in Healthy Individuals
Experimental studies of dietary lycopene in healthy adult subjects have been used to
test the impact of lycopene on a number of variables. Two common themes are evident in
these intervention studies (See Table 2-1). First, when an increased amount of dietary lycopene
is consumed there is a corresponding increase in the plasma level of lycopene60, 61. Second,
findings from these studies indicate an increased amount of dietary intake of lycopene
11

consistently decreases biomarkers of inflammation (CRP levels) and biomarkers of oxidative
stress (lipid peroxidation)57, 60, 62-64. As well, several small studies have demonstrated the
variations of the bioavailability of lycopene, specifically in different food sources and when
delivered in different mediums (canned vs. raw, paste vs. juice, olive oil vs. sunflower oil) 65, 66.
Investigators have tested lycopene bioavailability and absorption rates and studied a
variety of food products containing lycopene, but only in very small sample sizes.60, 61, 66-68 For
example, the investigators in one intervention study tested 11 healthy individuals to determine
whether consumption of diced tomatoes cooked with olive oil resulted in higher plasma
lycopene concentrations than consumption of diced tomatoes cooked without olive oil67.
Plasma lycopene concentrations were measured after 5 days of a lycopene washout period and
again after a five-day dietary intervention. The investigators concluded that the addition of
olive oil to tomatoes greatly increased the absorption of lycopene as demonstrated by an 82%
increase in plasma trans-lycopene (P = < 0.001) and a 40% increase in cis-lycopene (P = 0.002)
concentrations67. A smaller intervention study conducted in Northern Ireland with 6 healthy
individuals tested two types of cooking oil with lycopene containing food products (tomato
soup and canned tomatoes)68. The consumption of tomato products with olive oil significantly
raised the plasma antioxidant activity from 930 ± 150 to 1118 ± 184 mmol/l, (p = .01) but no
effect was observed when the sunflower oil was used 68. This investigation suggests the
composition of oil used for cooking tomato products may affect the antioxidant activity and
bioavailability of lycopene.
Healthy individuals (n = 60; 30 men/30 women) who consumed a lycopene-free diet for
1 week were randomized to receive lycopene from eating Campbell's Condensed Tomato Soup ,
12

Campbell's Ready To Serve Tomato Soup or V8 Vegetable Juice , respectively, for 15 days60.
After the intervention period, total lycopene concentrations significantly increased for those
consuming condensed soup, ready to eat soup and V8 [by 0.784 ± 0.083 (123% increase, P <
0.0001), 0.545 ± 0.061 (57%, P < 0.01) and 0.569 ± 0.061 (112%, P < 0.0001) micro mol/Liter]
when compared to baseline levels, respectively60. This study demonstrates that serum lycopene
concentration changes as a result of intake of a variety of food products 60. Collectively, these
small intervention studies provide evidence to support the following when designing future
experimental studies: 1) the anti-inflammatory effect of lycopene; and 2) the importance of
considering bioavailability, food source and delivery medium when using dietary sources of
lycopene.
Epidemiologic Studies of Lycopene
Several large epidemiologic studies have been conducted. The combined evidence from
these studies suggests an inverse relationship between serum carotenoids in general and
lycopene specifically and cardiovascular disease risk69-73. In a large prospective, longitudinal
study of US male physicians, an association was found between increased vegetable intake and
lower risk of coronary heart disease, independent of other cardiac risk factors 74. Investigators
were able to detect a 25% risk reduction even at the low end of vegetable consumption (1-2
servings per day). Similar findings from Ness et.al23 and Law et.al75 lend support to the findings
in the Physician Health study. Cross sectional data from the National Health and Nutritional
Survey III (NHANES) 1988-1994 demonstrated an association between levels of five carotenoids
(lycopene included) and inflammation measured by CRP76. The NHANES data were from a large
sample (n = 4557) of young (mean age = 38.6 ± 8.6) healthy individuals. While these studies do
13

not specifically identify lycopene as a micronutrient of interest, nor do they specify HF as a
condition, there is enough evidence from these studies to provide a foundation for additional
inquiry related to the purpose of this paper.
Methods
The purpose of this paper was to examine the evidence about the impact of lycopene
dietary interventions in patients with HF. A search of Pub Med, CINAHL, and the Cochrane
Library was performed using the search terms ‘lycopene’, ‘antioxidants’, ‘heart disease’, ‘heart
failure’, ‘oxidative stress’, and ‘inflammation.’ The search was limited to the time period
between the years of 2000-2010 and to articles written in English. The following were inclusion
criteria: 1) research reports; 2) human studies; 3) observational studies of dietary lycopene
intake in patients with HF; 4) intervention studies of lycopene; and 5) dietary intake of food
products containing lycopene, not supplements. Each manuscript was read and reviewed for
content and applicability. The PubMed search resulted in the following results for each term
used: (See Table 2-2)
•

lycopene = 2682 articles

•

lycopene and heart disease =104 articles

•

lycopene and inflammation = 36 articles

•

lycopene and oxidative stress = 304 articles

•

antioxidants and HF = 2371 articles

•

lycopene and HF =3 articles
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Results
There were no intervention studies of dietary lycopene intake in patients with HF. Only
two studies have been conducted that lend support for the potential role of dietary lycopene in
patients with HF to reduce inflammation as evidenced by measurement of biomarkers of
oxidative stress. 77, 78
A case-control evaluation of patients with HF moderate (class II) and severe (class III) HF
according to NYHA classification (13 females, 17 males, 73.8 ± 7.4 years old; n= 30) were
compared to age-matched controls (25 females, 30 males, 76.3 ± 8.5 years old; n = 55).77
Investigators measured a circulating biomarker of oxidative stress (malondialdehyde-MDA) and
plasma antioxidants (Vitamin A, E and carotenoids) levels. Significantly higher levels of oxidative
stress and lower levels of plasma antioxidants were found in HF patients in comparison to
controls. Levels of oxidative stress were found to be higher in New York Heart Association
(NYHA) class III than in NYHA class II HF patients (p =.0012)77. The conclusion from this
particular investigation indicates an association exists between increased oxidative stress and
the general class of antioxidant carotenoids in patients with HF.
In a similar cross-sectional analysis (perhaps the same) by the Polidori et.al78, patients
with moderate (class II) and severe (class III) HF according to NYHA classification, (14 male, 16
female, 73.1 ± 7.4 years; n =30) were compared to age-gender matched controls (18 male, 12
female, 80.0 ± 17.4 years; n= 30)78 and were found to have significantly higher levels of plasma
F8, 12-isoprostanes. Isoprostanes are sensitive and specific markers of lipid peroxidation.
Levels of 8, 12-isoprostane F(2α)-VI were significantly higher in class III than in class II NYHA HF
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patients. The investigators also found the EF of HF patients to be inversely correlated to
isoprotane levels and directly correlated to plasma levels of lycopene.
These two studies, conducted by the same investigator, which had small sample sizes,
did find significant associations between plasma lycopene, biomarkers of oxidative stress and
the data do provide insight into the potential role of dietary lycopene to manage oxidative
stress in patients with HF.
Critique
In these small studies, investigators observed an association between HF patients and
two types of biomarkers of oxidative stress. The age of the patients in these studies is
representative of other HF samples. The sample would have been more inclusive if class I and
class IV NYHA patients were included in the analysis, as I-IV is representative of the complete
trajectory of HF disease status. Multiple drug therapies such as ACE inhibitors, beta blockers
and diuretics were considered in only one of the studies; this is of importance as many of these
drugs are considered to have antioxidant properties and could have confounded the results
when considered as a co-variate in the analysis. No differences were observed in these two
studies between HF patients with an ischemic or non-ischemic etiology. The investigators
excluded patients if they were smokers; this information would have added to the analysis as
smoking history appears to have an association with antioxidant status.79, 80
The observation of a significant association between EF of HF patients and plasma levels
of lycopene is of potential interest and warrants further studies in this area.
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Discussion
After completing this review of the literature, it is interesting to note that further
research has not been conducted and makes me wonder why this has not occurred. My
conjecture for the reason why research has not advanced in this area is because “nutrition
interventions” are not deemed as important as pharmacological interventions; there is not the
same level of funding available for nutritional interventions as there is available for
pharmacologic interventions. Specifically, I believe that medical practitioners are more
interested in providing drugs to patients than they are in taking the time to explain the
importance of nutrition and how patients with HF can make simple changes in lifestyle related
to nutrition. This conjecture is not evidence based, but is the experience of an advanced
practice nurse with 20 years experience in caring for HF patients. The science of advancing
treatment strategies for HF patients is primarily focused on pharmacologic interventions. The
money for research is primarily available in pharmacologic studies. Hence, nutritional
interventions appear to be designated to those individuals who have an interest in providing
more than just pharmacologic treatment options to patients with HF.
Conclusion
In conclusion, there is sufficient evidence to support the following regarding lycopene
and HF: 1) HF is a condition of increased inflammatory response; 2) oxidative stress poses an
independent threat at the cellular level and contributes to the inflammatory response; 3) there
are endogenous and exogenous antioxidant defense systems that can reduce the level of
inflammation and oxidative stress; 4) lycopene is a potent antioxidant that is associated with
reduced biomarkers of lipid peroxidation and oxidative stress. For the reasons elucidated, there
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has been no research on the impact of dietary lycopene intake on inflammation in HF. Yet,
given the safety of dietary lycopene intake and based on the known scientific foundation, it is
plausible to begin scientific inquiry into the potential role of lycopene in reducing inflammation
and oxidative stress in patients with advanced cardiovascular disease such as HF. This process
of scientific inquiry will help to elucidate whether increased dietary intake of lycopene has a
cardioprotective role in HF specific to inflammatory and oxidative stress components in the
pathophysiologic process.
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CHAPTER THREE
Higher Dietary Lycopene Intake is Associated with Longer Cardiac Event-Free Survival in
Patients with Heart Failure
Introduction
Heart failure (HF) remains a major cause of early death and is associated with high
morbidity resulting in significant personal, societal and economic burden.82 Hospitalizations
account for the majority of expenses incurred in the care of patients with HF. Rates of HF
hospitalizations have increased by approximately 200% over the past decade.83 Additional
strategies for managing HF are needed to reduce the personal and economic costs of HF.
Recent evidence suggests that nutrition may play a role in improving outcomes in
patients with HF.13, 84-86 Findings point to specific macro and micronutrients that may slow the
trajectory of HF by decreasing the inflammatory process associated with HF, and reducing the
amount of oxidative stress.13, 48, 87, 88 Antioxidants such as lycopene, selenium and vitamin D
may be targets for nutritional therapy. Lycopene in particular may be beneficial in HF due to
potential cardioprotective effects. Numerous investigations in humans and animal models have
demonstrated an inverse relationship between serum lycopene levels and risk of cardiovascular
disease (CVD)62, 89-91.
The major source of dietary lycopene in the United States is fresh and processed fruits
and vegetables, particularly tomatoes. Heat during processing alters the molecular structure of
lycopene making it more bioavailable to human tissue39, 62, 92. Unfortunately, processed foods
containing high levels of lycopene also contain high levels of sodium. Research investigating the
potential benefits of lycopene must also consider the sodium content of such foods93, 94.
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Therefore the purpose of this study was to determine the association between lycopene intake
and cardiac event-free survival in patients with HF stratified by sodium intake levels.
Methods
Study Design
This was a longitudinal prospective study in which levels of dietary lycopene and sodium
intake were measured at baseline. This study was part of a larger study titled “BMI, Nutrition,
Inflammation, and Heart Failure Outcomes” (PI- Terry A. Lennie, R01NR 009280). Patients were
followed for up to three years. Rehospitalizations and cardiac mortality data were obtained to
examine the relationship between dietary lycopene intake and cardiac event-free survival after
stratifying patients by sodium intake levels.
Sample and setting
Patients were recruited from outpatient HF clinics associated with academic health
centers in Kentucky, Indiana and Georgia. Patients were included if they had a diagnosis of
chronic HF confirmed by a cardiologist and were on a stable medication regimen for at least 3
months. Patients were excluded if they had a history of acute myocardial infarction or
cerebrovascular attack within the previous 6 months, were cognitively impaired, and had a comorbid terminal illness or an inflammatory condition that suppressed appetite or required
dietary restrictions other than sodium. A total of 246 patients were invited to participate. Six
patients declined, 7 patients withdrew, 5 patients were lost to follow-up and 16 provided
incomplete food diaries resulting in a final sample size of 212 patients.
Measurement of variables
Dietary lycopene and sodium intake
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Dietary intake was measured by four day food diaries that included three weekdays and
one weekend day. Food diaries were analyzed using the Nutrition Data System for Research
(NDSR; Nutrition Coordinating Center, Minneapolis, MN)95. The analysis provided four day
averages of patient’s intake with data on 156 individual nutrients including lycopene and
sodium.
Event-free survival
The primary outcome of this study was event-free survival. This is defined as the
composite end point of time to first HF hospitalization (emergency department or inpatient
admission with a primary diagnosis of HF) or a cardiac related death during the follow-up
period. Data on hospitalization events or death were collected from patients/ family member
interviews, medical record review, hospital administrative records and death certificates. A
clinical expert on the research team reviewed all the data on reasons for hospitalization to
ensure accurate categorization. Because of the possibility that a patient was admitted to
various hospitals, patients/families were interviewed to obtain self-reports of admissions,
which were then used to validate or augment electronic medical record data.
Covariates
Covariates included New York Heart Association (NHYA) functional classification, age,
gender, body mass index (BMI) left ventricular ejection fraction (LVEF) and prescribed
medications (i.e., ACE inhibitors, beta-blockers, angiotensin II receptor blockers, digoxin and
diuretics). Total co-morbidity score was obtained using the Charlson Co-Morbidity Index 96, 97.
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Procedure
The study received approval from the Institutional Review Board at each enrollment
site. Patients with HF were referred to the study by cardiologists and nurse practitioners. All
patients gave written informed consent prior to participating. Demographic and clinical
characteristics were collected at baseline. Patients were visited in their homes by a trained
research nurse who provided detailed oral and written instructions for recording all food and
beverages consumed during the four day food diary collection. Digital scales were provided to
measure the weight of each food. Food models were also provided for patients to estimate
serving sizes when they found that weighing food was impractical (e.g., when eating at a
restaurant). Patients were asked to provide a return demonstration of food diary recording and
food measurement as a review of the procedure. Patients were also telephoned on the first day
of the food diary recording to answer any questions they may have had. The morning after
completion of the food diary, the patient met with the dietitian who reviewed the completed
food diary. This process was to verify the serving sizes, obtain any missing information, and
clarify food preparation techniques. These review sessions typically lasted 30-45 minutes.
Lycopene and sodium levels were then determined using the NDSR software program for
nutrient analysis. Lycopene and sodium daily consumption levels were totaled and then
averaged over the four days of record keeping.
Statistical Analysis
Data were analyzed using SPSS for Windows 17.0. Patients were dichotomized based on
the median value for lycopene intake and the two groups were further stratified by the cutpoint of 3 grams of sodium intake. For the purpose of data analysis, patients with a lycopene
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intake less than median were defined as low lycopene group and those with an intake of greater
than median split were defined as the high lycopene group. Independent t tests or chi square
tests were used to compare the differences of sample characteristics between lycopene groups.
Cox proportional hazard regression was used to compare the differences in cardiac event-free
survival of patients in the lycopene groups stratified by sodium intake while controlling for age,
gender, HF etiology, BMI, NYHA classification, LVEF and total co-morbidity burden. The
proportional hazard assumption was confirmed through visual inspection of the log (-log)
survival curves.
Results
Patient characteristics
Patient characteristics of the total sample and of the high and low lycopene intake
groups are shown in Table 3-1. The average age of patients enrolled in this study was 60 years
±12 (range 23-97 years). Sixty-eight percent of the patients were Caucasian and 29 % were
African-American. Almost one-third of patients had preserved systolic function with LVEF >
40%. The common co-morbidities were hypertension and diabetes mellitus. The mean four day
average intake of lycopene was 4091 mcg/day ± 4940 (range from 0 - 31,529) and the median
was 2471 (25th percentile = 915, 75th percentile = 5076) mcg/day. Fifty one percent of patients
had daily sodium intake greater than 3 grams per day. The average sodium intake of the high
lycopene group was greater than the low lycopene group (Table 1). The majority of patients in
both lycopene groups were classified as NYHA functional classification of II or III, and were on
appropriate HF medication regimens of ACE inhibitors, diuretics and beta blockers.
Cardiac events
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During the follow-up period there were a total of 2 patients who died (1.0%) and 41
patients (19.3%) who were hospitalized with a primary diagnosis of HF or experienced a cardiac
related death.
Using Cox hazard regression modeling, patients with a dietary lycopene intake above
the median had longer event-free survival than those with a dietary lycopene intake below the
median after multivariate adjustment. In the stratum of patients with sodium intake levels
above 3 grams per day, the low lycopene group demonstrated 3 times greater risk of having a
cardiac event compared to patients in the high lycopene group (Table 2). Adjusted survival
curves for high versus low lycopene groups with each stratum of sodium intake are depicted in
Figure 1A and 1B. Higher intake of lycopene was associated with longer event-free survival in
both strata of sodium intake. In the stratum of patients with sodium intake less than 3 grams
per day, low lycopene intake presented a 3.3 times greater risk of cardiac events when
compared to the high lycopene group.
Discussion
This is the first study to demonstrate that higher intake of lycopene independently
predicted longer cardiac event-free survival regardless of sodium intake in patients with heart
failure. These findings are important because they suggest a fruitful avenue for future research
that some have been reluctant to follow due to the high sodium content of many tomato-based
foods. Our findings suggest that the antioxidant properties of dietary lycopene may be more
important to the health of patients with health failure than reducing sodium intake alone.
Our findings about lycopene are consistent with those of prior researchers who have
reported inverse relationships between lycopene and the development of cardiovascular
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disease (CVD)98. The previous evidence in support of the role of lycopene in the prevention of
CVD comes primarily from observational studies on normal and at risk populations. 3, 19, 62, 89, 91,
99-101

For example, in The Rotterdam Study, using a case-control design, investigators
assessed the presence of calcified plaques in the abdominal aorta as a clinical indication of
atherosclerosis4. The study sample consisted of 108 individuals with moderate to severe
atherosclerosis compared to 108 age-gender matched controls without atherosclerosis. The
investigators reported an inverse relationship between serum levels of lycopene and the
presence of atherosclerosis when using a logistic regression model with multivariate
adjustment4. The odds ratio for the highest compared to the lowest quartile of serum lycopene
was 0.55 (95% CI, 0.25-1.22)4.
The strongest population based evidence for lycopene comes from a multi-center case
control study (EURAMIC) that evaluated the relationship between adipose tissue antioxidant
status and acute myocardial infarction.70 Needle aspiration biopsy samples of the adipose tissue
were taken after a myocardial infarction and levels of alpha carotene, beta carotene, lycopene
and tocopherol were measured. Only lycopene was found to be protective with an odds ratio of
0.52 for the comparison of the 10th and 90th percentiles (95% CI, 0.33-0.82; p = 0.005).70 A doseresponse was also observed between each quintile of adipose tissue lycopene and the risk of
myocardial infarction. The protective potential of lycopene was at the highest among
individuals with the highest polyunsaturated fat stores70.
Evidence about the effectiveness of lycopene in heart disease has recently been
extended to patients with HF. In a series of observational studies, Polidori et al. evaluated
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plasma levels of malondialdehyde (MDA) and F2 isoprostane as biomarkers of oxidative stress
and antioxidants levels (vitamin A, vitamin E, lutein, zeaxanthin and lycopene) in 30 HF patients
with NYHA Class II and III compared to 30 age-gender matched controls (18 male, 12 female,
80.0 ± 17.4 years)77, 78. Class II NYHA patients with HF had significantly lower levels of markers
of oxidative stress (MDA and F2 isoprostane levels) and significantly higher levels of antioxidant
intake (vitamin A, vitamin E, lutein, and lycopene) than NYHA III patients. Ejection fraction was
inversely correlated with MDA levels in HF patients when compared to the controls. A positive
correlation was found between plasma levels of lycopene, lutein and Vitamin A and ejection
fraction, thus suggesting increased hemodynamic function of the heart in the presence of
dietary antioxidants. These findings further suggest that antioxidants are depleted in patients
with worse HF which may be linked to increased oxidative stress or perhaps as a result of
lifestyle, disease or age-related reasons that can facilitate oxidative stress 77, 78.
In a retrospective analysis of subjects enrolled in the Third National Health and Nutrition
Examination Survey, Wood and Johnson reported a relationship was found between tomato
consumption, serum lycopene levels and HF risk in individuals with periodontitis102. This doseresponse relationship existed after adjusting for demographic, medical and lifestyle factors (p =
0.05). When data were further adjusted for serum lycopene levels, the relationship between
tomato consumption and HF risk in periodontally involved individuals remained high (p = < .05)
102

.
Approximately 80% of the sodium in the average American diet comes from processed

foods and for the past two decades the average daily sodium intake among adults was greater
than 3200mg103. Dietary sodium indiscretion is considered to be a precipitant in >20% of
26

patients hospitalized for decompensated HF and high sodium intake is an independent risk
factor for HF exacerbation104-106. Because the richest sources of lycopene (processed tomatobased products such as ketchup, tomato juice, and pizza and spaghetti sauces) are also some of
the highest in sodium, clinicians commonly have patients with HF avoid these foods. Our data
suggest that foods containing high levels of lycopene may be beneficial regardless of their
sodium content.
A potential limitation of this study was the use of self-recorded food diaries. We used a
combination of strategies to increase the accuracy of the food diaries. Our participants were
given detailed instructions for the diary by an experienced HF research nurse. In addition to the
verbal instruction, written and graphic materials were provided to each participant. Patients
also were given digital food scales to assist with measurement of food portions. Food models
were utilized to help with estimation of serving sizes. Food diaries were reviewed with the
patient by a dietician. Further motivation to accurately complete the food diary was enhanced
by providing a nutritional analysis report to the patient. Another limitation to this study is that
we did not obtain a direct measurement of oxidative stress or inflammation and therefore we
cannot conclude the potential mechanism responsible for our findings.
Our findings do support the potential cardioprotective benefit of higher lycopene intake
in the presence of increased sodium levels in food products consumed by patients with HF.
Increased sodium intake in patients with HF is associated with an increase in fluid retention that
is often responsible for the exacerbation of HF symptoms. However, the potentially detrimental
effect of increased sodium content in processed food products may not overshadow the benefit
of lycopene in HF patients. However, further studies are needed to clearly delineate the
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interaction of lycopene and sodium in patients with HF, and the results from our study should
not be interpreted as suggesting that sodium restriction is unnecessary in patients with HF,
even in the presence of high lycopene intake.
Conclusion
Future research should include use of randomized control trials of various levels of
dietary lycopene intake in HF patients stratified by their usual sodium intake. A diet with a high
lycopene intake has the potential to improve cardiac event free survival outcomes in HF
patients. The study of dietary factors that lead to a diet rich in antioxidants is essential for
optimization of interventions aimed at reducing the burden of HF. Additional research should
be conducted to examine the potential impact of lycopene from a variety of food products on
the inflammatory process in patients with HF.
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CHAPTER FOUR
Lycopene Dietary Intervention: A Pilot Study in Patients with Heart Failure
Introduction
Heart failure (HF) is recognized as a significant contributor to cardiovascular mortality
and morbidity rates in North America and most Western civilizations and is considered one of
the most problematic threats to healthcare. HF is commonly a result of ischemic heart disease
or hypertension. Despite advances in the treatment of HF, the mortality and hospitalization
rates for HF continue to rise with a 45% re-hospitalization rate at 6 months and a 27% rehospitalization rate at 90 days.107, 108 Over 800,000 hospitalization visits are reported annually
by Medicare and these visits consume the majority of healthcare dollars required to care for
patients with HF.109
The connection between increased antioxidant intake and reduced cardiovascular
disease (CVD) risk has been demonstrated in several epidemiologic and observational studies.1-4
Although HF has a major inflammatory component and ischemic cardiovascular disease is the
most common cause of HF, few investigators have examined the potential impact of increased
antioxidant intake in improving outcomes in HF patients.
There is substantial evidence to indicate that antioxidants play a role in reducing the
inflammatory and oxidative stress processes that are thought to be responsible for
atherosclerosis in CVD.110-112 Lycopene is a superior antioxidant found in natural and processed
food products and is considered to be one of the most efficient at reducing free radicals.89, 113
Given the role of inflammation in HF, a novel strategy for preventing or delaying the
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complications of HF may be to increase lycopene intake in the diet. Thus, the purpose of this
randomized, controlled pilot study was to test the effect of an intervention consisting of intake
of a food product concentrated with lycopene (V8® juice) on biomarkers of inflammation and
oxidative stress in patients with HF.
Specific Aim #1: Compare the impact on serum levels of uric acid and C-reactive protein
(CRP) in a group of patients with HF in the intervention group who consume 11 ounces of V8®
juice daily to levels in a control group of HF patients who did not consume V8® juice daily
controlling for HF severity as reflected by b-type natriuretic peptide (BNP).
Hypothesis #1: Compared to a control group and to their own baseline, HF
patients randomized to consume 11 ounces of V8® juice daily for one month will
have lower levels of uric acid and CRP regardless of BNP level.
Specific Aim #2: To test adherence to the intervention by comparing plasma levels of
lycopene in the intervention versus control groups.
Hypothesis #2: Compared to a control group and to their own baseline, HF
patients randomized to consume 11 ounces of V8® juice daily will have higher
levels of plasma lycopene after one month of intervention.
Specific Aim #3: To determine the impact of consumption of 11 ounces of V8® juice
daily on sodium intake.
Methods
Study Design
This study was a two-group randomized controlled intervention trial in which patients
were randomized to either an intervention group (n=22) or usual care/control group (n=18).
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Patients were recruited from outpatient and inpatient healthcare settings in Central Kentucky.
The intervention group was given one 11.5 ounce can of V8® 100% Low-Sodium Vegetable juice
to drink each day for 30 days while consuming their normal habitual diet. The usual care group
continued to consume their habitual diet. Data for both groups was collected at baseline and
one month post intervention. Data collection included sociodemographic and clinical
information, random 24 hour dietary food recalls, and blood samples for levels of uric acid, CRP,
BNP and lycopene.
Sample and Setting
Patients were recruited from a community hospital and an academic outpatient
cardiology clinic in Central Kentucky. Eligibility criteria for patients in this study included: 1)
confirmed diagnosis of HF, with preserved or non-preserved ejection fraction, 2) hospitalized
for HF within the last 6 months; 3) able to read and write English; 4) living independently (i.e.,
not institutionalized). Patients were excluded from the study if they: 1) were younger than 21
years of age; 2) had end stage renal disease, a co-morbidity with a known inflammatory
component, or a disease or illness that was predicted to cause death within the next 12
months; 3) had impaired cognition; or 4) disliked V8 juice. Forty three patients were invited to
participate in the study. Three declined to participate due to time constraints. No patients
withdrew or were lost to follow-up during the one month time frame. The final sample size was
40 patients. One baseline blood sample was dropped in the laboratory, therefore providing 39
baseline samples of lycopene and 40 post intervention samples of lycopene.
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Measurement
Plasma Lycopene
Plasma lycopene was obtained from venous blood (approximately 5mL) that was drawn
via needle and syringe from the lower forearm into EDTA vacutainer tubes (Fisher Scientific,
Pittsburg, PA). Plasma was immediately separated from red blood cells by centrifuging at 1000
x g at 4˚C for 10 min. Blood plasma was then placed into cryovials and stored at -80˚C until high
performance liquid chromatography (HPLC) analysis.
Lycopene extraction: Plasma (0.5mL) was mixed with 0.5mL ethanol containing 0.1%
butylated hydroxytoluene and 2mL of HEAT (10 hexane/6 ethanol/7 acetone/7 toluene). The
mixture was vortexed and then centrifuged for 5min at 300 x g. The upper non-polar layer was
removed and the remaining aqueous plasma mixture was extracted twice more. The three
non-polar extracts were combined and dried under nitrogen. The dried extract was stored at 80˚C until HPLC-PDA analysis.
Lycopene HPLC-PDA (photodiode array) analysis: Samples were reconstituted in 1:1
200µL methanol/ Methyl tert-butyl ether (MTBE) and filtered through a nylon syringe filter.
Samples were analyzed using an HPLC system (Waters 996) interfaced with a PDA detector
(Waters 2996). Separation was achieved using a YMC C-30 column (Waters Corp., Milford, MA).
A 30 min. gradient method employing methanol and MTBE was used with a flow rate of
1.3mL/min, column temperature = 30°C, and injection volume = 20 µL. Lycopene was
quantified using an external calibration curve.
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C-Reactive Protein
C-reactive protein was measured using point-of-care methodology (Cholestech LDX
Diagnostics, Inverness Medical Innovations). Venous blood (approximately 5mL) was withdrawn
via a needle and syringe from the patient and placed into a purple top vacutainer. Serum was
removed from the vacutainers using a pipette, 0.4ml was placed onto the Cholestech hsCRP
cartridge, then placed into the Cholestech LDX® analyser. The Cholestech LDX® system uses
reflectance photometry. This method of determining CRP levels has been demonstrated to
provide reproducible, accurate and valid results.114
Uric Acid
Uric acid was measured using standardized laboratory assay analysis at the University of
Kentucky clinical laboratory. Venous blood (approximately 5ml) was withdrawn via a needle and
syringe from the patient and placed into a green top vacutainer. Samples were refrigerated as
necessary and taken to the clinical research laboratory for analysis using.
B-type Natriuretic Peptide
B-type natriuretic peptide was measured using a point-of-care machine. Venous blood
(approximately 5mL) was withdrawn via a needle and syringe from the patient and placed into a
vacutainer tube. Serum was removed from the vacutainers using a pipette, 0.1ml was placed
onto the Triage BNP cartridge, then into the Triage BNP® analysis machine (Biosite Diagnostics,
Inverness Medical Innovations). This method of determining BNP levels has been demonstrated
to provide reproducible, accurate and valid results.115
Sociodemographic and clinical characteristics
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In order to characterize patients, they were interviewed and answered questionnaires
to obtain the following information: age, gender, marital status, smoking history, exercise
patterns, comorbid conditions, NYHA classification, lifestyle behaviors and current medications,
including vitamins, over the counter drugs or herbal supplements. The research nurse collected
information on comorbid conditions using the interview format of the Charlson Comorbidity
Index (CCI)116, 117. This index was developed to classify comorbid conditions that might change
the risk of mortality. The index predicts short-term and long-term mortality in several situations
including patients with heart disease including HF, cancer, stroke, renal disease, and frail
elders97, 117.
Dietary intake assessment
Dietary nutrient intake of sodium and lycopene was assessed using a 24-hour diet recall
method to determine (1) natural intake of lycopene in order to describe the lycopene intake in
food products consumed in the control and intervention groups, and (2) sodium intake, as
lycopene containing foods that are processed often contain higher levels of sodium. A 24 hour
diet recall was collected at the baseline data collection visit and then randomly once a week for
3 weeks for a total of 4 recalls for each patient. The research nurse provided each patient with
detailed instructions on how the diet recall information would be obtained. The information
provided during the 24-hour recall was recorded onto a secure laptop and then entered into a
computer software program titled Nutrition Data System (NDS) software (NCC, University of
Minnesota)118. This program was used to analyze the nutrient content of the dietary recall. The
NDS software provides output for 126 nutrient and nutrient ratios from the food intake data.
The database, which is updated twice yearly, contains ingredient information for over 19,000
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foods including over 8000 brand name and many ethnic foods118. There are data for over
160,000 food variants differing in preparation method or ingredients. The research nurse
collecting data completed a certification process as a nutrition interviewer using the NDSR
software.
Research Procedures
The Institutional Review Board at the University of Kentucky granted permission to
conduct this study. All patients gave informed written consent. A research nurse performed all
procedures. The research nurse was an experienced cardiovascular advanced practice nurse
who has completed certified training on protection of human subjects in research. During the
first interview with the patients, the research nurse obtained sociodemographic and clinical
data. Data about medications and supplements was obtained from the patient and verified
through a review of the medical record. The research nurse also determined patients’ New York
Heart Association (NYHA) functional class by interviewing patients and determining their ability
to perform their usual activities and the occurrence of any symptoms with those activities. The
patient interview and questionnaires were completed at the baseline visit and again at the
post-intervention visit one month later. The visits took place at a prearranged time such as
before or after a cardiology clinic visit, cardiac rehabilitation session, in their home or at a place
of convenience the participant chose.
Patients were randomized to one of two groups following completion of baseline data
collection. A computer generated random number/block chart was utilized. Patients in both
groups were given detailed instructions regarding 24-hour dietary recall. Serving size
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estimation charts were provided to patients to assist with accuracy in conducting diet recalls.
The dietary recalls took between 15-20 minutes to complete.
Intervention
Patients randomized to the intervention group received a month’s supply of V8® 100%
Low-Sodium Vegetable juice (30 cans). Patients were asked to consume one can each day. They
were instructed that the entire can of juice could be consumed at one time or at separate times
as long as the entire can was consumed each day. Patients were also asked to keep track of
how many total cans they consumed during the month; this was to facilitate fidelity to the
intervention. V8® is vegetable juice, which is tomato based. Each 11.5 ounces of V8® juice
contains the following: 24 mg of lycopene; 70 calories; 140 mg of sodium; vitamins A and C;
820 mg of potassium; 2% of the recommended daily allowance for iron and magnesium; and 3
grams of fiber. This product contains a variety of vegetables (i.e., tomatoes, carrots, celery,
beets, parsley, lettuce, watercress, and spinach)119.
Statistical Analysis
The research nurse reviewed all questionnaires for completeness and legibility while the
patients were still present. All data analyses were conducted using SPSS version 17.0 and a P
value of < .05 was considered statistically significant. Descriptive analyses are presented as
frequencies and means ± standard deviations as appropriate to the level of measurement of the
variables. To compare baseline differences in sociodemographic and clinical characteristics
between the two treatment groups, t-tests or chi-square were used. Intention to treat
princip5les were applied to all data analysis. First, repeated measures ANCOVA was used to
assess whether the changes over time in the outcome measures differed between the
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intervention and control groups, controlling for BNP level. Then, multifactorial repeated
measures ANCOVA was used to evaluate whether gender or BNP interacted with group to
produce a differential impact on CRP and uric acid levels.
Results
Patient Characteristics
Characteristics of the total group and of the groups compared are displayed in Table 1. A
total of 40 patients who were all categorized as NYHA class II or III were enrolled. Most patients
had an ischemic HF etiology. There were no significant differences between patients in the
control group or the intervention group with respect to age, gender, body mass index, HF
etiology, NYHA classification, medications prescribed, smoking history or exercise patterns
(Table 3-1). All patients who enrolled in the study completed the study. There was only one side
effect reported in relation to drinking V8 juice daily and that was an increase in bowel
movements.
Specific Aim 1
Repeated measures ANCOVA revealed that the intervention and control groups were
similar on baseline measures of uric acid and CRP (Table 4-2). There were no differences at
baseline or across time in the covariate, BNP, between or within the groups. There was no
impact of the intervention on uric acid or CRP levels and there were no changes across time in
the control group in uric acid level or CRP (Table 4-2).
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Multifactorial repeated measures ANCOVA revealed that there was a gender by group
by time effect on CRP (p = 0.024 for the interaction; Figure 1), but not uric acid (p > 0.05 for
interaction and main effects; Figure 4-2) levels. There was no effect of the covariate, BNP level.
Among women in the intervention group there was a significant decrease in plasma CRP levels
at the post-intervention time point. There was no change in CRP levels among men in the
intervention group, but there was a decrease across time in the control group (Figure 4-1).
In order to explore potential reasons for the gender difference in the impact of the
intervention, we compared men and women on baseline BMI and CRP levels. There were no
differences between women and men in BMI (31.9 ± 9.7 vs 30.7 ± 6.7, respectively; p = 0.638).
There were difference in CRP levels between women and men (5.69 ± 3.5 vs 2.86 ± 2.62,
respectively; p = 0.01).
Specific Aim 2
Plasma lycopene levels significantly increased in the intervention group after daily
consumption of V8® 100% vegetable juice for 30 days, while there was no change in the control
group (See Figure 4-2; p = 0.02). There was no interaction of gender and group with regard to
the effect of the intervention on lycopene levels (p = 0.37). Plasma lycopene levels increased in
both men and women over time in the intervention group, but not in the control group.
Specific Aim 3
There was no significant group by time interaction on sodium intake (See Table 3; p =
0.237). There was no main effect of either time or group on sodium intake (Table 3, p = 0.153).
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Discussion
This is the first study in which a dietary lycopene intervention has been tested in a
sample of patients with HF. To date, there have been only two other studies in which the role of
dietary lycopene in patients with HF was assessed. In both studies, there was a positive
association between plasma lycopene levels, oxidative stress and HF77, 78, but both of these
studies were observational. In order to come to any firm conclusions about the effect of
lycopene in patients with HF, randomized, controlled studies are needed.
In our randomized, controlled study, we did not see an impact of the intervention on
either CRP or uric acid levels in the total group. We did, however, see a differential effect of
gender in the effect of the intervention on CRP levels, but not uric acid. In women, the
intervention resulted in a significant decrease in CRP across time, but not in men.
There are three major potential explanations for our finding of a gender effect in the
intervention. The possibilities include (1) greater adherence to the intervention in women than
in men, (2) the effect of BMI and adiposity, and (3) the higher CRP levels seen in women. With
regard to the first potential explanation, there is published evidence that women are more
adherent to prescribed HF regimens than men.120 There was, however, no evidence in our
sample that women were more adherent than men. Lycopene levels increased significantly in
both men and women in the intervention group over time, while remaining unchanged in the
control group.
With regard to the second potential explanation for our findings, increased BMI and
adiposity found in women may be plausible reasons. The adipose tissue produces inflammatory
cytokines such as interleukin-6 and tumor necrosis factor-alpha, which contribute to
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atherosclerosis. IL-6 enhances liver production of CRP. Levels of inflammatory markers in obese
persons (BMI > 30 kg/m2) are considered independent predictors of CVD. Lycopene increases in
adipose tissue and may exert its action on inflammatory cytokines. Abdominal adiposity has
been associated with risk of CHD in women121, 122. Higher waist-hip-ration (WHR) and greater
waist circumference have been found to be independently associated with a significantly
increased age-adjusted risk of CVD and HF.121, 123, 124 In the Nurses’ Health Study, women with a
WHR of 0.88 or higher had a relative risk (RR) of 3.25 (95% confidence interval, 1.78-5.95) for
CVD compared with women with a WHR of less than 0.72.121 There was no gender difference
in BMI level in our sample of patients. However, we did not have a measure of abdominal
adiposity, most commonly measured by waist circumference or WHR. This additional
measurement may have shed additional light onto our findings.
With regard to the third potential explanation for our findings, women have higher
levels of CRP than do men.125 For example, women participants enrolled in the Women’s Health
Study had a median CRP level of 0.42mg/dL compared with 0.28mg/dL in men.126 In our sample,
women had significantly higher baseline CRP levels than men. Often, the effect of a variety of
interventions (e.g., cardiac rehabilitation, weight loss, intake of healthy foods) is greater in
those in whom the outcome of interest is most negatively affected. That is, those who have the
most to gain (or lose), often show the largest effects of an intervention, at least initially.127-132
Thus, it is plausible that the substantially higher levels of CRP seen in the women in our study
allowed the intervention to better exert its effects.
There is sufficient evidence to support that CRP plays a direct role in inflammation. 133
The fact that our study found CRP levels decreased in response to a dietary intervention is a
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positive finding. Any decrease in CRP levels, such as the one observed in our study, has the
ability to reduce the risk of further cardiac events and is considered to be of important value to
clinicians and patients. 125, 134 A CRP in the highest quartile >0.73mg/dL had a five times greater
risk of developing an acute myocardial infarction or stoke compared to those in the lowest
quartile.126 CRP levels have also been shown to predict mortality in patients with dilated
cardiomyopathy and to have an inverse association with left ventricular function in patients
with HF.135 136 If CRP levels have increased in patients affected by HF, they will further increase
with the severity of the pathology and be associated with a higher rate of mortality
independently of any ischemic cause.46, 136
Our data also indicate that increased consumption of lycopene containing food products
results in increased plasma levels of lycopene. These data support other findings that increased
dietary intake of lycopene is reflected in plasma samples, indicating the bioavailability of
lycopene in human plasma57, 60, 137. Adherence to the lycopene intervention was observed in
both women and men in our sample.
Uric acid levels did not change as a result of the intervention, suggesting serum uric acid
may not be a robust indicator of oxidative stress in patients with HF. High serum uric acid levels
have been identified as a strong, independent marker of impaired prognosis in patients with
moderate to severe CHF138. Uric acid excretion depends on renal function and may be
compromised by diuretic treatment in these patients. The increased accumulation of reactive
oxygen species (ROS) as a by-product of xanthine oxidase activity, is thought to be one of the
underlying pathologic characteristics of increased uric acid in HF139. Inflammatory immune
activation and increased ROS accumulation (See Figure 4-Pathway of Inflammation and
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Oxidative Stress”), along with up-regulation of xanthine oxidase activity may contribute to
oxidative stress found in the setting of HF140 141. However, our study did not find serum uric
acid to be robust indicator of oxidative stress in a sample of patients with HF. This may be a
result of the small sample size or that uric acid production occurs upstream in the pathway of
oxidation and inflammation (See Figure 4).
Processed foods containing high levels of lycopene also contain high levels of sodium.
Approximately 80% of the sodium in the average American diet comes from processed foods.
Dietary sodium indiscretion is considered to be a precipitant in >20% of patients hospitalized
for decompensated HF and high sodium intake is an independent risk factor for HF
exacerbation. 104-106 Data from an earlier investigation suggest that foods containing high levels
of lycopene may be beneficial regardless of their sodium content142 The findings in the current
study did not indicate an increase in sodium intake between the two treatment groups.
However, even if a small increase in sodium levels had occurred, the benefit of the strong
antioxidant lycopene used in the intervention may not have had a negative impact on patients
with heart failure.
An important challenge in translating these findings into clinical treatment strategies
relates to the fact that most clinical studies have been designed on top of established
pharmacological therapy, whereas most experimental studies test novel interventions without
concomitant drug regimens such as ACE inhibitors or beta-blockers. However, our study tested
a randomized intervention on top of evidence-based drug regimens for patients with HF and
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still found an impact of a dietary intervention. This is exciting and demonstrated a fruitful area
of additional research related to dietary lycopene interventions.
With regards to the feasibility of this randomized, controlled trial of a dietary
intervention with lycopene, we found patients with HF were able to adhere to the intervention
as evidenced by a compliance rate of 100%. We also found this was an easy and inexpensive
intervention to implement. The V8® juice cost less than $1.00 per serving and is found in most
urban and rural grocery stores. The patients did not report any ill effects from drinking the
lycopene product for 30 days and only one person reported a mild side effect of increased
bowel movements. This intervention was a simple and easily implemented dietary intervention
and was well accepted and followed by a sample of patients with difficult self-management
regimens.
Limitations
Limitations exist when investigating the impact of a single micronutrient in a complex
condition such as HF. First, this investigation was a conducted in a small sample of patients with
HF. A larger sample size may assist in understanding mechanistic pathways for the interaction
we observed. A larger sample also needs to be studied in order to confirm the presence of a
gender interaction with the intervention. Secondly, the biological measurements that were
obtained in this study were collected at only two different time points and may not be
reflective of overall inflammatory status or oxidative stress in patients with HF.
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Conclusion
The study of the role of dietary or whole food sources of micronutrients as interventions
for inflammation and oxidative status in patients with HF is novel. To date, investigators have
largely studied supplements as sources of micronutrients. Lycopene is a natural plant
compound found in fruits and vegetables. Lycopene-containing products are inexpensive,
readily available, shelf-stable, and versatile. In a sample of patients with HF who received a
dietary lycopene intervention, we found a significant increase in plasma lycopene levels. Serum
CRP levels, as a biomarker of inflammation, significantly increased in the intervention group but
within females only. These findings suggest the naturally occurring antioxidant lycopene
interacts with gender to affect CRP levels in a sample of patients with HF. Although a
physiologic mechanism is unclear, additional studies will help clarify this finding. This study
provides insight to the potential role of lycopene in HF and may lead to additional treatment
strategies. These findings are a preliminary step in a process of establishing efficacy of a specific
dietary intervention with antioxidants that may have an effect on inflammation and oxidative
stress in HF.
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Chapter Five
Conclusions and Discussion

The enormous impact heart failure (HF) places on individuals and on our healthcare
system continue to drive the search for cost-effective treatment strategies. HF affects nearly 6
million people in the United States alone and the number of new cases is expected to increase
by more than 600 thousand cases each year.8, 9 Projected medical costs for the treatment of HF
are expected to increase by approximately 200% by the year 2030.143 Current treatment
strategies include multiple drug regimens with the evidenced-based use of angiotensinconverting enzyme inhibitors (ACE), beta-blockers (BB), diuretics, and spironalactone.144
Invasive procedures for the treatment of HF include placement of implantable cardiodefibrillators (ICD) and cardiac resynchronization therapy (CRT).144 Both of these strategies
account for the high costs related to treatment of HF. In addition to rising treatment costs,
there is an increase in the number of patients with HF due to the overall aging of the
population.143 Cumulatively, these issues are the momentum for researchers to find novel
therapeutic and economical interventions that are easily combined with current treatment
strategies.
The overall goal of treatment for HF is to reduce the substantial symptom burden that
accompanies HF. HF is a condition of chronic exacerbations of volume overload and myocardial
injury resulting from an intricate relationship between biochemical and biological mechanisms.
Recent research has provided evidence that inflammation and oxidative stress contribute to the
development and progression of HF.40, 145
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Inflammation and oxidative stress, independently and mutually, can reduce myocardial
contractility leading to a reduction in cardiac index. At the cellular level, inflammation increases
endothelial dysfunction via an inflammatory pathway activated by direct antigenic stimulation
or cytokine release in response to hemodynamic stress.42, 48, 50 Inflammatory cytokines, once
thought to be produced solely by the immune system, are now known to be synthesized by the
cardiomyocyte and can stimulate myocardial dysfunction by remodeling of the myocardium
interstitium through myocyte hypertrophy, apoptosis, and endothelial damage. 146, 147
Oxidative stress is the outcome when there is an imbalance between the reactive
oxygen species (ROS) production and the antioxidant defense mechanisms in the body.112, 148, 149
Oxidative injury occurs when the system is overwhelmed by free radicals and modification
occurs to organic molecules.112, 150, 151 Antioxidants provide protection by scavenging and
detoxifying the free radicals, thus maintaining a homeostatic balance at the cellular level.47, 152
Antioxidant nutrients may slow the progression of HF because of their ability to inhibit
damaging oxidative and inflammatory processes. Chapter two of this dissertation was a review
of the current research literature related to antioxidants and heart failure. Specifically, I
reviewed the literature to identify any investigations with the antioxidant lycopene used as a
dietary intervention with HF patients. As a result of this review, I found that there were no
intervention studies using lycopene in patients with HF, but that there to be strong evidence to
support the role of antioxidants in cardiovascular disease.69, 71-73, 113 I also found strong evidence
supporting the role of inflammation and oxidative stress for improving outcomes in patients
with HF40, 50, 112, 145, 150, 153, 154. Several studies have been conducted with lycopene and other
antioxidants in healthy individuals and an inverse relationship has been observed between
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increased lycopene intake and cardiovascular disease risk.59, 60, 62, 63, 67, 89, 101, 155-158 To date
there have been two case-control studies in which lycopene was investigated as the variable of
interest in a sample of HF patients.77, 78 Significantly higher levels of oxidative stress and lower
levels of plasma antioxidants were found in HF patients in comparison to controls. Among HF
patients, and ejection fraction (indicating disease severity) was found to be inversely correlated
to isoprotane levels (biomarker of oxidative status) and directly correlated to plasma levels of
dietary lycopene.77, 78 Collectively, these data provide evidence for the potential role of dietary
antioxidants in reducing nflammation and oxidative stress, thus potentially reducing symptom
burden in patients with HF.
Chapter three of this dissertation is a longitudinal prospective study in which levels of
dietary lycopene and sodium intake were measured. Rehospitalizations and cardiac mortality
data were obtained to examine the relationship between dietary lycopene intake and cardiac
event-free survival after stratifying patients by sodium intake levels. Dietary intake was
measured by four-day food diaries. Food diaries were analyzed using the Nutrition Data System
for Research (NDSR; Nutrition Coordinating Center, Minneapolis, MN).95 Patients were grouped
by the median split of lycopene level of 2471 mcg/day and stratified by daily sodium intake
levels above and below 3 grams. Patients were followed for up to three years to collect data on
HF hospitalization and cardiac mortality for event-free survival analysis. Cox proportional
hazard regression was used to compare differences in cardiac event-free survival between
higher and lower lycopene intake groups within each stratum of sodium intake level. Lycopene
intake above 2471 mcg/day was associated with longer cardiac event-free survival compared
with lower lycopene intake after controlling for age, gender, HF etiology, body mass index,
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NYHA functional class, LVEF, and total comorbidity score (p = .003). The worst cardiac eventfree survival was observed in the low lycopene intake group regardless of sodium intake level (>
3 grams HR = 3.01; p = .027 and < 3 grams HR= 3.34; p = .023). These data suggest an increased
dietary lycopene intake has the potential to improve cardiac event-free survival in patients with
HF independent of sodium intake, thus lending support to the role antioxidants may have in
patients with HF.
An intervention study was designed to test the impact of dietary lycopene on
biomarkers of inflammation and oxidative stress specifically in patients with HF. This study is
addressed in Chapter Four of this dissertation and was supported by the consistent protective
effect of lycopene found in epidemiological, tissue and experimental studies.
A randomized-control feasibility trial was conducted with a sample of 40 HF patients
assigned patients to one of two groups. The lycopene intervention group received 24 mg of
lycopene intake per day by drinking an 11.5 ounce serving of V8 100% vegetable juice daily for
30 days. Group 2 (usual care) continued their usual diet. Four randomized phone calls were
used to collect 24 hour diet recalls from the patients. We obtained serum lycopene, uric acid
(biomarker of oxidative stress), C-reactive protein (biomarker of inflammation), and b-type
natriuretic peptide (biomarker of HF disease severity) to determine the impact of the lycopene
dietary intervention.
In this study we used repeated measures ANCOVA to assess whether the changes over
time in the outcome measures differed between the intervention and control groups,
controlling for BNP level. Then, multifactorial repeated measures ANCOVA was used to evaluate
whether gender or BNP interacted with group to produce a differential impact on CRP and uric
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acid levels. We also used repeated measures ANOVA to test the impact of the intervention by
gender. The results of this investigation found plasma lycopene levels increased insignificantly
in the intervention group compared to the control group respectively (.51mmol/L to
.76mmol/L, p = .002; .56mmol/L to .58mmol/L. There was also a significant interaction
between CRP group and gender in the impact of the intervention on CRP levels; CRP levels
decreased significantly in the intervention group in women and but not in men, (p = .024). Uric
acid and BNP did not demonstrate a change related to the intervention as hypothesized in this
study. These findings suggest the naturally occurring antioxidant lycopene interacts with gender
to affect inflammation, as measured by CRP, in an intervention of increase dietary lycopene in a
sample of patients with HF.
The feasibility study and the longitudinal study combined are the beginning of a
program of research specifically focusing on the potential role of dietary lycopene in reducing
inflammation and oxidative stress in patients with HF. The potential impact of a dietary
intervention to reduce symptom burden in HF is of great interest to clinicians and researchers
as it poses a novel, innovative treatment strategy. A dietary intervention with a food product
high in lycopene, such as V8 juice once a day, is an economical and easily combined treatment
strategy with, very limited, if any side effects for patients with HF.
Additional studies are needed to further identify physiologic mechanisms of lycopene
and to identify appropriate biomarkers to measure oxidative stress and inflammation in chronic
HF as these remain unclear. Larger samples of patients with HF should be studied to validate
the findings from the feasibility study. Antioxidants other than lycopene may be responsible for
the impact of the intervention, or it may be a combination of antioxidants found in V8 juice. A
49

thorough examination of specific antioxidants and combined antioxidants should be conducted
in similar studies.
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Table 1-1: Definition of Terms- obtained from Taber’s Cyclopedic Medical Dictionary,
Nineteenth Edition
antioxidant- a agent that prevents or inhibits oxidation. A substance that may protect cells
from the damaging effects of oxygen radicals, highly reactive chemicals that play a part in
atherosclerosis, some forms of cancer, and reperfusion injuries.
bioactive- affecting living tissues
biochemical- of or related to biochemistry, the chemistry of living things, the science of
chemical changes accompanying the vital functions of plants and animals
carotenoid- one of a group of more than 500 yellow, orange, or red fat soluble pigments found
naturally in fruits and vegetables and acting as antioxidants in the body
endogenous- produced or originating from within a cell or organism
inflammation- an immunological defense against injury, infection or allergy, marked by
increases in regional blood flow, immigration of white blood cells, and release of chemical
toxins
micronutrient- any of the chemical elements required in minute quantities for growth of an
organism
nutrient- a nutritious ingredient or substance in food
nutrition- the series of processes by which an organism takes in and assimilates food for
promoting growth and replacing worn or injured tissues
oxidation- any process in which oxygen combines with an element or substance
peroxidase- any oxioreductase enzyme that acts as a catalyst in reactions in which a peroxide is
reduced
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peroxide- any oxide containing the O2 group in which the two atoms of oxygen are linked by a
single bond
phytochemical - chemical processes associated with plant life, and the chemical compounds
produced by plants
reactive oxygen species- a phrase used to describe a variety of molecules and free radicals
(chemical species with one unpaired electron) derived from molecular oxygen. Molecular
oxygen in the ground state is a bi-radical, containing two unpaired electrons in the outer shell
(also known as a triplet state). If one of the two unpaired electrons is excited and changes its
spin, the resulting species (known as singlet oxygen) becomes a powerful oxidant as the two
electrons with opposing spins can quickly react with other pairs of electrons, especially double
bonds.
scavenger - anything that removes impurities or refuse
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Table 2-1: Dietary intervention studies with Lycopene in healthy Individuals
Study Author
Agarwal et. al,
200157

Subjects
20 healthy individuals
10 male
10 female

Type and duration of intervention
Randomized crossover design
Placebo= 0 mg lycopene
Tomato juice = 50mg lycopene (500 ml)
Spaghetti sauce = 40 mg lycopene (126 g)

Results
1) Daily intake of spaghetti sauce or
juice significantly increased serum
levels of lycopene.
2) the avg. increase of any dietary
treatment over placebo was 2-fold
3) dietary lycopene significantly
lowered lipid oxidation measures
(TBARS)

Bose &
Agarwal,
200762

50 healthy &
30 CHD
Selected to
intervention

200 g cooked tomatoes = 25mg of lycopene
60 days

Hadley, et.al
200360

60 healthy
Randomized to
intervention

Jacob, et.al
200863

24 healthy
Randomized to
intervention

1) Campbell’s condensed soup =35mg lycopene
2) Campbell’s ready to serve soup= 23mg
lycopene
3) V8 juice = 25mg lycopene
15 days
1) 250 ml tomato juice with 90mg of Vit C twice
daily
2) 250 ml of tomato juice with 870mg Vit C
twice daily14 days

1)Significant improvement in serum
levels of enzymes involved in
antioxidant activity
2) Decreased lipid peroxidation rates
3) No significant changes in lipid
profiles
1) Increased protection of
lipoproteins to oxidative stress
2) Lycopene isomers change rapidly
with variation in dietary intake

Bub, et.al
200064

23 non-smoking men

Feeding study
1) 2 week intake of low carotenoid content
2) 2 week intake of 330 ml tomato juice=40mg
lycopene
3) 2 week intake of 330ml carrot juice= 15.7mg
α-carotene & 22.3mg β-carotene
4) 2 week spinach powder = 11.3mg of lutein
and 3.1mg β-carotene
8 weeks

Frohlich, et.al
200561

17 non-smoking
volunteers
Randomized to
intervention

1) 145-320 g tomatoes/day = 12.5mg lycopene
2) 94-101 g tomato juice/day = 12.5mg
lycopene
3) 25-28 g tomato puree/day = 12.5mg
lycopene
4 weeks

Unlu, et.al
200581

11 healthy nonsmoking subjects

Van het Hof
et.al 200065

33 volunteers, divided
into 2 groups by
gender

Feeding study
1) 300g Salsa w/avocado and w/o avocado &
3 slices of fat free bread
2) 220g Salad with carrots, lettuce, baby
spinach & 40g fat free Italian salad dressing
with 2 slices of fat-free bread-8 weeks
Split plot design- heat treatment and
homogenization
A pasta meal served at lunch for 4 cons. days
(no other fruits or vegetables were served on
these days) served with macaroni, ham and a
white sauce and a dessert of custard
1.canned tomatoes- 55 min of heat at 100
degrees Celsius
2.canned tomatoes- blended, homogenized
and heated
3. canned tomatoes- minimally heated at 80 C
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1)Reduction in serum total
cholesterol levels and CRP with
tomato juice consumption in both
groups
2) Cholesterol reduction correlated
with lycopene uptake
1)Tomato juice consumption
increased TBARs by 12% and
increased lag time for lipoprotein
oxidation- reducing LDL oxidation
2) Carrot juice and spinach powder
had no effect on lipid peroxidation

1) Following intervention, plasma
lycopene increased significantly
2) Supplementation did not affect
levels of tocopherols and ascorbic
acid in plasma
3) Lycopene isomerization changes
within the body after ingestion
1) Lycopene and β- carotene
absorption from salsa with avocado
was significantly higher than the
control meal

1) Additional heat and
homogenization enhanced the
release of lycopene; additional
heating was not always significant.
2) short term increased lycopene
intake is a good model to compare
the bioavailability from different
food sources

Table 2-2: Literature Search
Search Terms

PubMed

CINAHL

Cochrane

Lycopene

2682

406

4

Lycopene & HF

3

2

0

Lycopene & oxidative stress

304

42

1

Lycopene & inflammation

76

14

8

Lycopene & heart disease

104

10

7

HF & antioxidants

2371

55

1
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Table 3-1: Patient characteristics N = 212

Characteristics

(%) or Mean ± SD
Total

Lycopene ≤

Lycopene >

(n = 212)

2471 mcg/day

2471 mcg/day

60 ± 12

59 ± 12

61 ± 13

Male

143 (67.5)

66 (62.3)

77 (72.6)

Female

69 (32.5)

40 (37.7)

29 (27.4)

30.5 ± 7.6

30.5 ± 7.4

30.4 ± 7.8

Normal weight (< 25.0)

49 (23.1)

24 (22.6)

25 (23.6)

Overweight (25.0 to 29.9)

60 (28.3)

26 (24.5)

34 (32.1)

Obese ( ≥ 30.0)

103 (48.6)

56 (52.8)

47 (44.3)

NYHA

I

15 ( 7.1)

4 ( 3.8)

11 (10.4)

functional

II

81 (38.2)

40 (37.7)

41 (38.7)

class

III

87 (41.0)

48 (45.3)

39 (36.8)

IV

29 (13.7)

14 (13.2)

15 (14.2)

Heart

Non-ischemic heart disease

122 (57.5)

64 (60.4)

58 (54.7)

failure

Ischemic heart disease

90 (42.5)

42 (39.6)

48 (45.3)

ACE inhibitors

143 (67.5)

71 (67.0)

72 (67.9)

ARB II*

39 (18.4)

14 (13.5)

25 (23.8)

Digoxin

62 (29.2)

30 (28.8)

32 (30.2)

Age (years)
Gender

Body mass index (kg/m2)

etiology
Medication
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β blocker

185 (87.3)

95 (89.6)

90 (84.9)

Diuretics

163 (76.9)

78 (74.3)

85 (81.0)

Aldosterone antagonist

45 (21.2)

25 (23.8)

20 (18.9)

Left ventricular ejection fraction (%)

33.9 ± 14.0

34.0 ± 14.9

33.8 ± 13.2

< 40%

136 (64.2)

66 (62.3)

70 (66.0)

3.0 ± 2.0

3.0 ± 1.9

3.0 ± 2.1

Hypertension

147 (69.3)

77 (73.3)

70 (67.3)

Diabetes mellitus

80 (37.7)

41 (38.7)

39 (36.8)

3256 ± 1193

3029 ± 1087

3483 ± 1254

Less than 3,000 mg/day

109 (51.4)

60 (56.6)

49 (46.2)

Greater than 3,000 mg/day

103 (48.6)

46 (43.4)

57 (53.8)

Total comorbidity score

Sodium (mg/day)*

Figure Legend: ACE= angiotensin converting enzyme; ARB II= Angiotension II receptor blocker;
NYHA= New York Heart Association; * p < 0.05 in the independent t-test
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Figure 1A and1B. Difference in time to event between 2 groups with higher and lower lycopene
intake stratified by sodium intake
Survival curves were adjusted for age, gender, HF etiology, BMI, LVEF, NYHA class, and total
comorbidity score after stratifying by sodium intake.
Figure 1A

Figure 1B
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Table 4-1: Patient Characteristics
Characteristics

N (%) or Mean ± SD
Total

Intervention

Control

(n = 40)

(n= 22)

(n= 18)

65 ± 9

65 ± 11

65 ± 9

.999

Male

23

8 (35)

15(65)

.131

Female

17

10 (59)

7 (41)

31 ± 8

30 ± 5

32 ± 9

.257

II

28 (70)

16 (57)

12 (43)

.677

III

12(30)

6 (50)

6 (50)

Age (years)
Gender

Body mass index (kg/m2)
NYHA class

Heart failure

Non-ischemic

6 (15)

5 (83)

1 (17)

etiology

Ischemic

40 (85)

17(50)

17 (50)

Medication

ACE inhibitors

35 (88)

16 (46)

19 (54)

β blocker

30 (75)

17 (57)

13 (43)

Diuretics

19 (48)

9 (47)

10 (53)

Current

8 (20)

4(50)

4(50)

Former

20 (50)

11(55)

9 (45)

Never

12/40 (30)

6 (50)

6 (50)

< 1 hour/week

21/40 (53)

11(52)

10 (48)

> 1 hour/ week

19/40 (47)

11 (58)

8 (42)

Baseline

167 ± 198

196 ± 237

132 ± 133

Smoking History

Exercise frequency

BNP Levels, pg/ml
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P value

.130

.987

.935

.726

.316

Table 4-2: Serum C-reactive Protein and Uric Acid Pre- and Post-Intervention Compared
Between the Groups Using B-type Natriuretic Peptide as a Covariate

C-reactive Protein mg/L*

Uric Acid mg/dl*

Intervention

Control

Intervention

Control

Baseline

3.4 ± 3.1

4.8 ± 3.4

7.2 ± 1.5

7.2 ± 2.3

Post-Intervention

3.1 ± 2.8

4.5 ± 3.8

7.2 ± 1.3

7.3 ± 2.5

Legend: Post-intervention was 30 days after baseline; *p > 0.05 for time and group effect
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Table 4-3: Sodium and Lycopene Levels by Dietary Intake

Sodium intake*

Baseline

Total

Intervention

Control

Total*

Intervention

Control

2671 ±

2858 ±1389

2443 ±

9310 ±

10543 ±

7802 ±

1055

12849

14174

11235

2474 ± 879

14775 ±

23317 ± 8332

4336 ±

1252

PostIntervention

Lycopene intake

2864 ±

3182 ±1063

1036

11926

5545

Legend: Sodium = mg/day; Lycopene = mcg/day; Post-intervention was 30 days after baseline;
*p > 0.05 for time and group effect
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Figure 4-1: C-reactive Protein Levels Pre- and Post-Intervention Compared Between Groups by
Gender

p = 0.024 for the
interaction of group and gender

Figure Legend- F= Female; M= Male
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Figure 4-2: Uric Acid Levels Pre- and Post-Intervention Compared Between Groups by Gender

p = 0.284 for the
interaction of group and gender

Figure Legend- F= Female; M= Male
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Figure 4-3: Plasma Lycopene Compared Across Time Between the Groups

Figure Legend- Plasma lycopene = mmol/L; Pre = Baseline measurement; Post = after
intervention for 30 days
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Figure 4-4: Pathway of Inflammation and Oxidative Stress in Patients with Heart Failure
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